Glucose biosensors market seen reaching $30.88 billion by 2030

The global glucose biosensors market is projected to grow from $18.83 billion in 2026 to $30.88 billion by 2030, driven by rising diabetes rates, digital diabetes tools and demand for continuous monitoring. North America held the largest market share in 2025 as the industry expands across wearable, non-invasive and mobile-connected devices.

Why it matters: - Glucose biosensors are becoming a core tool for diabetes management as more patients need frequent blood sugar checks. - The market’s projected growth signals rising demand for home monitoring, point-of-care testing and connected health tools. - Faster adoption of non-invasive and wearable monitoring could change how people track diabetes day to day.

What happened: - The Business Research Company projected the glucose biosensors market will grow from $18.83 billion in 2026 to $30.88 billion by 2030. - The forecast implies a 13.2% compound annual growth rate over the period. - The company said the market reached $16.72 billion in 2025 and grew to $18.83 billion in 2026 at a 12.6% CAGR. - The report was released Aug. 7, 2026. - The company also published a free sample report and a full market report.

The details: - Glucose biosensors measure glucose in samples such as blood or interstitial fluid. - Their main use is diabetes management, where frequent monitoring helps patients adjust medication and lifestyle. - The market’s recent growth has been driven by more diabetes cases, stronger demand for home-based monitoring devices, better biosensor sensitivity, growth in point-of-care diagnostics and higher patient awareness. - Future growth is tied to digital diabetes management tools, non-invasive monitoring methods, personalized healthcare, biosensor research and development and AI-driven glucose analytics. - Key trends include wider use of continuous glucose monitoring systems, demand for wearable biosensors, integration with mobile health platforms, progress in non-invasive technologies and better real-time data accuracy. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast suggests glucose monitoring is moving from a clinical device category into a broader digital health market. - The focus on AI, wearables and mobile integration points to a market where convenience and data quality are becoming as important as basic measurement. - Rising pre-diabetes registrations in England underscore how screening and early intervention can expand demand beyond diagnosed diabetes patients. - The UK’s National Health Service reported in June 2024 that 549,000 additional people in England were identified in 2023 as being at risk of type 2 diabetes. - The same data brought the number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with general practitioners to 3,615,330, up from 3,065,825 in 2022.

What's next: - The market is expected to keep expanding through 2030 as more patients adopt connected monitoring and non-invasive tools. - The company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated trend analysis. - Further growth will likely depend on how quickly biosensor makers improve accuracy, comfort and integration with digital health systems.

The bottom line: - Glucose biosensors are shifting from a niche medical device to a fast-growing digital diabetes platform, with demand set to rise sharply through 2030.